Patents by Inventor Ester Fernandez-Salas

Ester Fernandez-Salas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BET Bromodomain Protein Degraders with Cleavable Linkers
    Publication number: 20200277305
    Abstract: The present disclosure provides compounds represented by Formula (I): Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Y, ?, Ar, W, L, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I)I for use to treat a condition or disorder responsive to inhibition and/or degradation of BET bromodomains such as cancer.
    Type: Application
    Filed: September 12, 2018
    Publication date: September 3, 2020
    Inventors: Shaomeng Wang, Weiguo Xiang, Fuming Xu, Longchuan Bai, Ester Fernandez-Salas, Donna McEachern
  • Immuno-based botulinum toxin serotype A activity assays
    Patent number: 10703806
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: July 7, 2020
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton Garay, Lina S. Wong, D. Dianne Hodges, Kei Rogers Aoki
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20200190496
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 18, 2020
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Method of detecting cleaved SNAP25 in tissue samples
    Patent number: 10527620
    Abstract: Methods and compositions for detecting BoNT/A enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to BoNT/A cleaved SNAP25 and is able to preferentially detect BoNT/A cleaved SNAP25, as compared to intact (non-cleaved) SNAP25, in a tissue sample.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: January 7, 2020
    Assignee: Allergan, Inc.
    Inventors: Ron S. Broide, Brian Cai, Ester Fernandez-Salas, Joseph Francis, Catherine Rheaume
  • Degradable clostridial toxins
    Patent number: 10501731
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 10, 2019
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYS
    Publication number: 20190324041
    Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
    Type: Application
    Filed: July 8, 2019
    Publication date: October 24, 2019
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A
    Patent number: 10451621
    Abstract: The present specification discloses methods for detecting extremely low amounts of botulinum neurotoxin serotype A in samples, including complex matrices like blood, plasma, and serum.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: October 22, 2019
    Assignee: Allergan, Inc.
    Inventors: Joanne Wang, Anuradha Dixit, Kenton B. Abel, Swati Gupta, Ester Fernandez-Salas
  • METHOD OF DETECTING CLEAVED SNAP25 IN TISSUE SAMPLES
    Publication number: 20190317095
    Abstract: Methods and compositions for detecting BoNT/A enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to BoNT/A cleaved SNAP25 and is able to preferentially detect BoNT/A cleaved SNAP25, as compared to intact (non-cleaved) SNAP25, in a tissue sample.
    Type: Application
    Filed: June 14, 2019
    Publication date: October 17, 2019
    Inventors: Ron S. Broide, Brian Cai, Ester Fernandez-Salas, Joseph Francis, Catherine Rheaume
  • Immuno-based retargeted endopeptidase activity assays
    Patent number: 10345306
    Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: July 9, 2019
    Assignee: Allergan, Inc.
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • FORMULATIONS OF BIOLOGICS FOR INTRAVESICAL INSTILLATION
    Publication number: 20190022195
    Abstract: Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.
    Type: Application
    Filed: April 16, 2018
    Publication date: January 24, 2019
    Inventors: Eric A. Forssen, Patrick M. Hughes, David C. Rupp, Terrence Hunt, Gary Shimizu, Joseph Francis, Ron S. Broide, Ester Fernandez-Salas
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20180119126
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: December 18, 2017
    Publication date: May 3, 2018
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Formulations of biologics for intravesical instillation
    Patent number: 9943576
    Abstract: Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: April 17, 2018
    Assignee: Allergan, Inc.
    Inventors: Eric A. Forssen, Patrick M. Hughes, David C. Rupp, Terrence Hunt, Gary Shimizu, Joseph Francis, Ron S. Broide, Ester Fernandez-Salas
  • Degradable clostridial toxins
    Patent number: 9850476
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: December 26, 2017
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20170283487
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Application
    Filed: January 6, 2017
    Publication date: October 5, 2017
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton Garay, Lina S. Wong, D. Dianne Hodges, Kei Rogers Aoki
  • IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYS
    Publication number: 20170248602
    Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays
    Publication number: 20170218334
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: Hong Zhu, Joanne Wang, Birgitte P.S. Jacky, D. Dianne Hodges, Ester Fernandez-Salas
  • Immuno-based retargeted endopeptidase activity assays
    Patent number: 9651553
    Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 16, 2017
    Assignee: Allergan, Inc.
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20160201046
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: March 28, 2016
    Publication date: July 14, 2016
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Degradable Clostridial toxins
    Patent number: 9297003
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: March 29, 2016
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Degradable clostridial toxins
    Patent number: 9284545
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: March 15, 2016
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki